Novel Lotion Formulation Using Polymeric Emulsion Technology for Improved Skin Moisturization and Drug Permeation in Patients With Psoriasis

EA Tanghetti; L Stein-Gold; JQ Del Rosso; S Weiss; T Lin; A Angel; R Pillai

EA Tanghetti

Center for Dermatology and Laser Surgery, Sacramento, CA

L Stein-Gold

Henry Ford Hospital, Detroit, MI

JQ Del Rosso

JDR Dermatology Research/Thomas Dermatology, Las Vegas, NV

S Weiss

Direct Dermatology, Palo Alto, CA

T Lin

Ortho Dermatologics,* Bridgewater, NJ *Bausch Health US, LLC is an affiliate of Bausch Health Companies Inc. Ortho Dermatologics is a division of Bausch Health US, LLC.

A Angel

Bausch Health US, LLC,* Petaluma, CA *Bausch Health US, LLC is an affiliate of Bausch Health Companies Inc. Ortho Dermatologics is a division of Bausch Health US, LLC.

R Pillai

Bausch Health US, LLC,* Petaluma, CA *Bausch Health US, LLC is an affiliate of Bausch Health Companies Inc. Ortho Dermatologics is a division of Bausch Health US, LLC.

Keywords

Polymeric Emulsion Technology, Psoriasis

Abstract

Abstract not available.

References

1. Svendsen et al. J Dermatolog Treat. 2019:1‑6.
2. Tanghetti et al. J Dermatolog Treat. 2019:1‑8.

Poster PDF

Published

Jan 28, 2020

How to Cite

Tanghetti, E., Stein-Gold, L., Del Rosso, J., Weiss, S., Lin, T., Angel, A., & Pillai, R. (2020). Novel Lotion Formulation Using Polymeric Emulsion Technology for Improved Skin Moisturization and Drug Permeation in Patients With Psoriasis. SKIN The Journal of Cutaneous Medicine, 4(1), S11. Retrieved from https://jofskin.org/33014/index.php/skin/article/view/824

Issue

Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)

Section

Poster Presentations at 2020 Winter Clinical Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

L Green, A Armstrong, CF Teller, S Bell, T Lin, Treatment of Psoriasis: A Survey on Patient Preference and Satisfaction , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
A Moore, L Green, S Bruce, N Sadick, E Tschen, P Werschler, S Dhawan, D Forsha, M Gold, S Guenthner, S Kempers, L Kircik, J Parish, M Rendon, P Rich, L Stein-Gold, S Tyring, R Weiss, A Nasir, C Schmitz, T Boodhoo, A Kaoukhov, D Berk, F Cook-Bolden, Ayman Grada, Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-blind Clinical Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
Z Draelos, F Cook-Bolden, L Green, E Guenin, G Martin, R Pillai, Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
L Stein-Gold, B Elewski, Z Draelos, T Lin, Safety and Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion in the Treatment of Females With Moderate-to-Severe Plaque Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
MG Lebwohl, J Sugarman, DM Pariser, J Bagel, T Lin, R Israel, Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
LF Eichenfield, B Elewski, JL Sugarman, T Rosen, A Gupta, R Pillai, T Lin, Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
F Cook-Bolden, J Soung, ST Guenthner, B Bumpass, T Lin, Efficacy and Safety of Halobetasol Propionate 0.01% Lotion in the Treatment of Females With Moderate-to-Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
SR Desai, B Glick, JQ Del Rosso, T Lin, Efficacy and Safety of Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
JI Silverberg, L Beck, M Boguniewicz, T Lin, AM Evans, DS Patel, T Rush, AR Swensen, Study of Adult Atopic Dermatitis and Comorbidities in the US Department of Defense Healthcare System , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
SK Tyring, LH Kircik, PS Yamauchi, N Anbalagan, T Lin, Efficacy and Safety of Halobetasol Propionate 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion in the Treatment of Moderate to Severe Plaque Psoriasis of the Lower Extremities , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)

1 2 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)